Eric Siemers, MD, Acumen Pharmaceuticals, Charlottesville, VA, explores the application of positron emission tomography (PET) imaging to determine amyloid positivity in Alzheimer’s disease (AD) clinical trials, with reference to the Phase I INTERCEPT-AD trial (NCT04931459). In this trial, PET scans with a standardized uptake value ratio (SUVR) greater than 1.2 were labeled as amyloid positive, while those with SUVR less than 1.0 were considered amyloid negative. Those with an SUVR between these values underwent further analysis by an expert to determine amyloid status, leading to the inclusion of some individuals with low centiloid values. Emerging research suggests that these patients may respond better to amyloid-targeting therapy, so should be included in clinical trials. However, Dr Siemens emphasizes that further research is required to establish optimal inclusion criteria based on amyloid PET imaging. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
